CliffBio
small molecule

ABILIFY

ARIPIPRAZOLE

Loss of exclusivityMarch 2027latest FDA-listed patent expiry
CompanyOtsuka Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameABILIFY
Active ingredientARIPIPRAZOLE
Strength30MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2002
Marketing statusRX

Listed patents

PatentExpiresType
8759350March 2027use U-1529
9125939July 2026use U-1749

More from Otsuka Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ABILIFY patent cliff — loss of exclusivity March 2027 | CliffBio